Syncor reports record earnings

Article

Pharmaceutical company Syncor attributes record first-quarter earnings to an increase in product prices and rapid growth—15% to 17% a year—in the cardiology market.Syncor’s net income for the quarter ending March 31 rose by 49% to $7.5

Pharmaceutical company Syncor attributes record first-quarter earnings to an increase in product prices and rapid growth—15% to 17% a year—in the cardiology market.

Syncor’s net income for the quarter ending March 31 rose by 49% to $7.5 million from $5 million for the same period a year ago. Net sales for the quarter increased by 20% to $149 million, up from $124 million for the same period of 1999.

Cardiolite, Syncor’s heart imaging agent, has a strong presence in the market, said Robert Funari, Syncor’s president and CEO. The company was able to increase many product prices while retaining customers, he added. This year, Syncor will add several new locations to its U.S. pharmacy business, create a line of PET products and services, and introduce iodine-125 seeds into the brachytheraphy market. I-125 seeds are used in radiation therapy.

Comprehensive Medical Imaging, a subsidiary of Syncor, operates 43 imaging centers in Florida, Arizona, and Southern California. In the third quarter of this year, CMI will open its first PET imaging center in Rancho Mirage, CA (SCAN 4/12/00). Last month, Syncor acquired MRI Trinidad and Tobago, an imaging center in Port of Spain, Trinidad and Tobago (SCAN 4/26/00).

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.